490 related articles for article (PubMed ID: 23627915)
1. Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Vuitton L; Koch S; Peyrin-Biroulet L
Curr Drug Targets; 2013 Nov; 14(12):1385-91. PubMed ID: 23627915
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib in ulcerative colitis.
Archer TP; Moran GW; Ghosh S
Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibition in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Expert Rev Clin Immunol; 2017 Jul; 13(7):693-703. PubMed ID: 28164724
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Danese S; Grisham M; Hodge J; Telliez JB
Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Vyas D; O'Dell KM; Bandy JL; Boyce EG
Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
[TBL] [Abstract][Full Text] [Related]
6. Update on Janus kinase antagonists in inflammatory bowel disease.
Boland BS; Sandborn WJ; Chang JT
Gastroenterol Clin North Am; 2014 Sep; 43(3):603-17. PubMed ID: 25110261
[TBL] [Abstract][Full Text] [Related]
7. The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment.
Kim JW; Kim SY
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768752
[TBL] [Abstract][Full Text] [Related]
8. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
9. The use of tofacitinib in the treatment of inflammatory bowel disease.
Weisshof R; Golan MA; Yvellez OV; Rubin DT
Immunotherapy; 2018 Aug; 10(10):837-849. PubMed ID: 29701124
[TBL] [Abstract][Full Text] [Related]
10. [Tofacitinib].
Döker S; Dewenter M; El-Armouche A
Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
[TBL] [Abstract][Full Text] [Related]
11. Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data.
Varyani F; Argyriou K; Phillips F; Tsakiridou E; Moran GW
Drug Des Devel Ther; 2019; 13():4091-4105. PubMed ID: 31819376
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tofacitinib treatment in ulcerative colitis.
Panés J; Gisbert JP
Gastroenterol Hepatol; 2019; 42(6):403-412. PubMed ID: 31101342
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib for the treatment of ulcerative colitis.
Izzo R; Bevivino G; Monteleone G
Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
[TBL] [Abstract][Full Text] [Related]
14. The use of Tofacitinib in the treatment of inflammatory bowel disease.
Nasonov EL; Abdulganieva DI; Fairushina IF
Ter Arkh; 2019 Mar; 91(2):101-108. PubMed ID: 31094180
[TBL] [Abstract][Full Text] [Related]
15. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
[TBL] [Abstract][Full Text] [Related]
16. Next generation of small molecules in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Gut; 2017 Feb; 66(2):199-209. PubMed ID: 27856614
[No Abstract] [Full Text] [Related]
17. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of tofacitinib for the treatment of psoriatic arthritis.
Abdulrahim H; Sharlala H; Adebajo AO
Expert Opin Pharmacother; 2019 Nov; 20(16):1953-1960. PubMed ID: 31456440
[No Abstract] [Full Text] [Related]
19. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
Teixeira FV; Damião AOMC; Kotze PG
Arq Gastroenterol; 2018; 55(2):198-200. PubMed ID: 30043874
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
Bannwarth B; Kostine M; Poursac N
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):753-61. PubMed ID: 23570265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
